Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma

D. M. Lurie, I. K. Gordon, Alain P Theon, C. O. Rodriguez, S. E. Suter, Michael S Kent

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Background: Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. Animals: Thirty-eight client-owned animals diagnosed with multicentric lymphoma. Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. Results: The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%. Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.

Original languageEnglish (US)
Pages (from-to)1064-1070
Number of pages7
JournalJournal of Veterinary Internal Medicine
Volume23
Issue number5
DOIs
StatePublished - Sep 2009

Fingerprint

Hemibody Irradiation
lymphoma
drug therapy
Canidae
Lymphoma
irradiation
Drug Therapy
dogs
dosage
remission
Dogs
confidence interval
Confidence Intervals
Therapeutics
prednisone
doxorubicin
cyclophosphamide
Prednisone
retrospective studies
Doxorubicin

Keywords

  • Combination therapy
  • Dogs
  • Efficacy

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma. / Lurie, D. M.; Gordon, I. K.; Theon, Alain P; Rodriguez, C. O.; Suter, S. E.; Kent, Michael S.

In: Journal of Veterinary Internal Medicine, Vol. 23, No. 5, 09.2009, p. 1064-1070.

Research output: Contribution to journalArticle

@article{af3cac56e20247dda9be76c29e96936e,
title = "Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma",
abstract = "Background: Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. Animals: Thirty-eight client-owned animals diagnosed with multicentric lymphoma. Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. Results: The median 1st remission was 410 days (95{\%} confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31{\%}. The median overall survival was 684 days (95{\%} CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44{\%}. Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.",
keywords = "Combination therapy, Dogs, Efficacy",
author = "Lurie, {D. M.} and Gordon, {I. K.} and Theon, {Alain P} and Rodriguez, {C. O.} and Suter, {S. E.} and Kent, {Michael S}",
year = "2009",
month = "9",
doi = "10.1111/j.1939-1676.2009.0353.x",
language = "English (US)",
volume = "23",
pages = "1064--1070",
journal = "Journal of Veterinary Internal Medicine",
issn = "0891-6640",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Sequential low-dose rate half-body irradiation and chemotherapy for the treatment of canine multicentric lymphoma

AU - Lurie, D. M.

AU - Gordon, I. K.

AU - Theon, Alain P

AU - Rodriguez, C. O.

AU - Suter, S. E.

AU - Kent, Michael S

PY - 2009/9

Y1 - 2009/9

N2 - Background: Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. Animals: Thirty-eight client-owned animals diagnosed with multicentric lymphoma. Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. Results: The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%. Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.

AB - Background: Sequential half-body irradiation (HBI) combined with chemotherapy is feasible in treating canine lymphoma, but prolonged interradiation intervals may affect efficacy. A 2-week interradiation interval is possible in most dogs receiving low-dose rate irradiation (LDRI) protocols at 6 Gy dose levels. Hypothesis: LDRI incorporated into a cyclophosphamide, doxorubicin, vincritine, and prednisone (CHOP)-based chemotherapy protocol is effective for the treatment of lymphoma in dogs. Animals: Thirty-eight client-owned animals diagnosed with multicentric lymphoma. Methods: Retrospective study evaluating the efficacy and prognostic factors for the treatment of canine lymphoma with sequential HBI and chemotherapy. Results: The median 1st remission was 410 days (95% confidence interval [CI] 241-803 days). The 1-, 2-, and 3-year 1st remission rates were 54, 42, and 31%. The median overall survival was 684 days (95% CI 334-1,223 days). The 1-, 2-, and 3-year survival rates were 66, 47, and 44%. Conclusions and Clinical Relevance: Results of this study suggest that treatment intensification by a 2-week interradiation treatment interval coupled with interradiation chemotherapy is an effective treatment for dogs with lymphoma.

KW - Combination therapy

KW - Dogs

KW - Efficacy

UR - http://www.scopus.com/inward/record.url?scp=70349682292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349682292&partnerID=8YFLogxK

U2 - 10.1111/j.1939-1676.2009.0353.x

DO - 10.1111/j.1939-1676.2009.0353.x

M3 - Article

C2 - 19627472

AN - SCOPUS:70349682292

VL - 23

SP - 1064

EP - 1070

JO - Journal of Veterinary Internal Medicine

JF - Journal of Veterinary Internal Medicine

SN - 0891-6640

IS - 5

ER -